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PCV1 COST-EFFECTIVENESS OF ACUTE ISCHEMIC STROKE IN CHINA: MARKOV MATRIX ANALYSES
Wang M Shenyang Pharmaceutical University, ShenYang, Liaoning, China OBJECTIVES: To measure economic consequences of NBP (Butylphthalide) for acute ischemic stroke in China. METHODS: A multi-center, randomized, double-blind control study was conducted, 220 patients were admitted into the treatment group and control group, the main regimen is A1 (Butylphthalide sodium chloride injection and Butylphthalide sodium chloride capsule), A2 (Butylphthalide sodium chloride injection), B (Ozagrel injection). We explored the MRS (modifi ed Rankin score) to establish Markov state transition model, with six different health states. The cost and effectiveness data were come from the studies based on Chinese acute ischemic stroke studies. Based on transferred Markov matrix, we will obtain the time period for disease steady-state and predict long-term costs and cost-effectiveness from the patient's perspective. RESULTS: A1 group reached the steady state fi rst, fi ve cycles (10 months), A2 and B group were behind a period. The steady state cost of A1 group involved 79,396.90 yuan, more than A2 group by 19,379.54 yuan, and 85,806.71 yuan for B group, compared with the extension days with no obvious signifi cant. At a steady state, the cost-effectiveness ratio of A1 Group's health state was 86.3 thousand yuan, A2 group 82.1 thousand yuan and B group 96.4 thousand yuan, Thus, economic results of A group (A1 and A2) were better than B group, A2 group slightly better than A1 group, but given the time to reach a steady state, the A1 group had more advantages of economic effects. CONCLUSIONS: Based on the results of this model-based economic analysis, A1 strategy was the most cost-effective option in comparisons with A2 and B strategies for acute ischemic stroke in China. Therapeutic interchange is not a well-accepted clinical practice in the medical society in Asia. Clinic blood pressure readings, patients' tolerance, and costeffectiveness were used as measures to evaluate the impact of a therapeutic interchange program implemented at a medical center in Taiwan. METHODS: Taipei Medical University-Wan Fang Medical Center initiated a therapeutic interchange program involving angiotensin II receptor blockers (ARBs). Data were retrospectively collected for 444 hypertensive outpatients who were converted from other ARBs to candesartan. Evaluation of therapeutic effi cacy, adverse effects associated with therapy, and drug costs was conducted before and after the program implementation. RESULTS: Patients who were converted to candesartan experienced no statistically signifi cant differences in blood pressure, and the average number of antihypertensive agents used per patient remained unchanged. A direct cost savings of US$62,237 was estimated for the 444 patients studied, which amounted to a savings of more than US$730,000 annually for all outpatients using ARBs. Only 3.15% of patients developed ADRs potentially related to the candesartan and none required hospitalization. CONCLUSIONS: Based on the results of this retrospective chart review, the present therapeutic interchange program was successfully developed and implemented. This is the fi rst study to establish the positive impact of a well-run ARBs therapeutic interchange program in Taiwan.
PCV2 SUCCESSFUL IMPLEMENTATION OF A P&T APPROVED THERAPEUTIC INTERCHANGE PROGRAM OF ANGIOTENSIN II RECEPTOR BLOCKERS IN A MEDICAL CENTER IN TAIWAN
PCV3 MIXED TREATMENT COMPARISON OF PROPHYLAXIS REGIMENS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN TOTAL HIP REPLACEMENT, HIP FRACTURE, TOTAL KNEE REPLACEMENT AND GENERAL SURGERY
Farris M 1 , LeReun C 2 , Lee J 3 , Tilden D 1 1 THEMA Consulting Pty Ltd, Pyrmont, NSW, Australia; 2 Independent Biostatistician, Carrigaline County, Cork, Ireland; 3 Sanofi -Aventis Australia, Sydney, NSW, Australia OBJECTIVES: To compare the effi cacy and safety of several different anticoagulant therapies in high-risk surgical patients using a mixed treatment comparison (MTC) approach. METHODS: A manual literature search for randomized double blind controlled trials (RDBCTs) was undertaken that compared any two of the following agents: enoxaparin, rivaroxaban, unfractionated heparin (UFH) or placebo and reported rates of venous thromboembolism (VTE) in patients undergoing total hip replacement, hip fracture surgery, total knee replacement and general surgery. Bayesian methods of MTC meta-analysis were applied to synthesize data from 31 RDBCTs. Safety data (defi ned as major hemorrhage) were extracted when available. Patients received prophylaxis for up to 15 days, or extended therapy up to 35 days postsurgery. RESULTS: All treatments were compared to placebo using the Odds Ratio as a measure of effi cacy. When compared to placebo, the incidence of VTE was reduced by ≥50% with prophylactic therapy post-hip surgery; patients undergoing extended prophylaxis with enoxaparin or rivaroxaban received the greatest benefi t, with a reduction in the risk of VTE of 87% or 95% respectively. Prophylaxis also reduced the incidence of VTE after knee surgery by ≥80%; patients treated with enoxaparin or rivaroxaban were 87% or 92% less likely to experience VTE, respectively, when compared to placebo. Prophylaxis after general surgery signifi cantly reduced the risk of VTE over placebo by ≥76%. The risk of major hemorrhage was highest with UFH, followed by rivaroxaban and enoxaparin. CONCLUSIONS: The MTC approach resulted in a comprehensive examination of the effect of thromboprophylaxis on the rate of VTE and major hemorrhage in high-risk surgery. Upon examining the body of clinical data, the evidence is clear: thromboprophylaxis is highly effective at preventing VTE in patients undergoing high-risk surgery. When compared with rivaroxaban and UFH, prophylaxis with enoxaparin resulted in similar and lower incidence of VTE respectively, with less major hemorrhage.
